ALLERGIC EYE DISEASES IN CHILDREN. MODERN VIEW ON PATHOGENESIS AND TREATMENT

The prevalence off allergic diseases has  been  significantly increased among  adults  and children during last 30-40 years. International study has  shown  that  the  frequency  of atopy  in developed  countries, including Russia,   is higher  than  in developing.  Often atopic dermatitis, started in infancy, can develop into an “allergic march”  — food allergy, followed by the formation of allergic rhinitis, allergic conjunctivitis and  other  allergic diseases. The problem  of prophylaxis and  treatment of allergic pathology  becomes actual  for these reasons. An opinion according some  preventive  measures has  changed in recent. It was  noted  that  in families  with many children, where  children  were  often  sick  with respiratory infections,  the  incidence  of allergic  diseases was  lower  than  among  rarely sick children.  It is explained by the  “hygienic theory” — insufficient “training” of the  Th1 response in rarely sick children.  Allergic diseases, which are  based on IgE-mediated inflammation,  have a common  pathogenetic nature and,  consequently, general  principles of therapy, in which, as  is well known,  antihistamines take  a significant  place.  This is cased by the  mandatory involvement of histamine  in the mechanism of development of the main symptoms of allergic diseases. Current  capabilities  of local ophthalmologic  antiallergic therapy includes medicines  with multiple action mechanisms, such as mast cell stabilizers, antihistamines, combined  agents, steroids and nonsteroidal anti-inflammatory effects. The latest generation antihistamine drug — olopatadine hydrochloride  0.2% is a new form of the molecule of olopatadine, which is intended  to increase the duration  of the action.  The article considers the main modern directions in prevention  and treatment of allergic diseases, including allergic eye diseases, which are  a manifestation of the underlying disease and have a common  pathogenetic nature to all atopic diseases, based on the IgE-mediated inflammation reaction.

1. Zaytseva O.V. [Modern aspects of the basic therapy of bronchial asthma in children under the age of 6 years]. Sovremennye aspekty bazisnoy terapii bronkhial'noy astmy u detey v vozraste do 6 let. [Pulmonology]. Pul'monologiya. 2014: 5:94‑100. (in Russ.)

2. Keil U1, Weiland SK, Duhme H, Chambless L. The International Study of Asthma and Allergies in Childhood (ISAAC): objectives and methods; results from German ISAAC centeres concerning traffic density and wheezing and allergic rhinitis. Toxicol Lett. 1996:86(2‑3):99‑103.

3. Ellwood P., Asher M., Beasley R. The International Study of Asthma and Allergy in Childhood (ISAAC): phase three rationaleand methods. Lung Dis. 2005:9(1):10‑6.

4. Wegmann T.G., Lin H., Guilbert L., Mosmann T.R. Bidirectional cytokine interactions in the maternal‑fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol. Today. 1993:14:353–356.

5. Braback, L, Hedberg, A. Perinatal risk factors for atopic disease in conscripts. Clin Exp Allergy. 1998;28:936–942.

6. Malek A., Sager R., Kuhn P. Am. J. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Reprod. Immunol. 1996:36: 248–255.

7. Buddington R.K. Can. J. Ontogenetic Development of Nutrient Transporters in Cat Intestine. Physiol. Pharmacol. 1994:72:251–259.

8. Roduit C, Frei R, Depner M, Karvonen AM, Onset and Progression in Childhood. JAMA Pediatr. 2017:22. doi: 10.1001/jamapediatrics.2017.0556.

9. Sánchez J, Sánchez A, Cardona, R.Particular characteristics of atopic eczema in tropical environments. The Tropical Environment Control for Chronic Eczema and Molecular Assessment (TECCEMA) cohort study. An Bras Dermatol. 2017:92(2):177‑183. doi: 10.1590/abd1806‑4841.20175140.

10. Strachan D. P. Hay fever, hygiene, and household size. BMJ. 1989 Nov 18; 299(6710): 1259– 1260. . Gibson PG, Henry RL, Shah S, Powell H, Wang H. Migration to a western country increases asthma symptoms but not eosinophilic airway inflammation. Pediatr. Pulmonol. 2003:36(3):209–15. DOI:10.1002/ppul.10323

11. Rogler G, Zeitz J, Biedermann L. The Search for Causative Environmental Factors in Inflammatory Bowel Disease. 2016;34 Suppl 1:48‑55. doi: 10.1159/000447283.

12. Schuijs MJ, Willart MA, Vergote K et all. Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. 2015:4;349(6252):1106‑10. doi: 10.1126/science.aac6623.

13. Iwata K, Fukuchi T, Hirai M, Yoshimura K, Kanatani Y. Prevalence of inappropriate antibiotic prescriptions after the great east Japan earthquake, 2011. 2017:96(15):e6625. doi: 10.1097/MD.0000000000006625.

14. Segura‑Egea JJ, Martín‑González J, Jiménez‑Sánchez MDC, Crespo‑Gallardo I, Saúco‑Márquez JJ, Velasco‑Ortega E. Worldwide pattern of antibiotic prescription in endodontic infections. Int Dent J. 2017: Apr 17. doi: 10.1111/idj.12287.

15. Johansson S. G. O., Bieber N., Dahl R.et al. Revised nomenclature for allergy for global use: Report of the nomenclature review committee of the World Allergy Organisation, October 2003. Journal of Allergy and Clinical Immunology. 2004:113: 832‑836.

16. Warner J. A. с соавт Warner JO, Warner JA. Fetal and early‑life origins of allergy. Pediatr. Allergy Immunol. 2014:25(1):7‑8. doi: 10.1111/pai.12201.

17. Warner, JA, Miles, EA, Jones, AC, Quint, DJ, Colwell, BM, and Warner, JO. Is deficiency of interferon gamma production by allergen triggered cord blood cells a predictor of atopic eczema? Clin Exp Allergy. 1994;24:423–430.

18. Abelson MB, Gomes PJ, Vogelson CT. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0,2% compared with placebo in patients with allergic conjunctivis or rhinoconjunctivitis: A randomized, double‑masked environmental study. Clin Ther. 2004;26:1237‑1248.

19. Vogelson C, Abelson M, Pasquine T. Preclinical and clinical antiallergic effect of olopatadine 0,2% solution 24 hours after topical ocular administration. Allergy Asthma Proc, 2004; 25:69‑75.

20. Lichtenstein S, Vogelson C, Well D. Olopatadine is safe and well‑tolerated in adults and children as young as three years of age. Presented at Western Society of Alergy, Asthma&Immunology Annual Meeting; Jan 19‑23, 2003.

21. Brockman HL, Momsen MM, Knudtson JR, Miller ST, Graff G, Yanni JM. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm. 2003; 11 (4): 247‑268.

22. Laner R, Finegold I, D'Arienzo P, Granet D, Epstein AB, Ledgerwood G. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the cohjunctival allergen challenge model. Curr Med Res Opin. 2004; 20: 2644‑2651.